# Zogenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zogenix

- Industry: Pharmaceuticals
- Headquarters: Emeryville, US
- Website: www.zogenix.com
- Total disclosed funding: $150M
- Latest round: Series C (Dec 7, 2009)
- Investors on record: 9

## About

Based in California, US, and founded in 2006, Zogenix Inc. operates as a biotechnology company that develops products used for the treatment of patients with central nervous system disorders and pain. They provide ZX008 (low-dose fenfluramine) for the treatment of Dravet syndrome and ZX008 (low-dose fenfluramine) for the treatment of Lennox-Gastaut syndrome (LGS).

## Funding rounds

- Series C, Dec 7, 2009, $35M — Abingworth, Domain Associates, Thomas, McNerney & Partners, Chicago Growth Partners, Scale Venture Partners, Clarus Ventures, Oxford Finance
- Series C, Sep 21, 2009, $36M — Abingworth, Domain Associates, Thomas, McNerney & Partners, Scale Venture Partners, Clarus Ventures, Oxford Finance Corporation
- Series B, Dec 26, 2007, $33M — Abingworth, Domain Associates, Thomas, McNerney & Partners, Scale Venture Partners, Clarus Ventures
- Series A, Sep 6, 2007, $30M — Domain Associates, Thomas, McNerney & Partners, Scale Venture Partners, Clarus Ventures
- Series A, Sep 7, 2006, $16M — Domain Associates, Thomas, McNerney & Partners, Scale Venture Partners, Clarus Ventures, Life Science Angels, Inc.

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B, Series C
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series A, Series B, Series C
- Scale Venture Partners (https://capitalatlas.ai/funds/scale-venture-partners) — Series A, Series B, Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B, Series C
- Life Science Angels, Inc. — Series A
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B, Series C
- Oxford Finance Corporation — Series C
- Chicago Growth Partners (https://capitalatlas.ai/funds/chicago-growth-partners) — Series C
- Oxford Finance — Series C